HIF-PH inhibitor

HIF prolyl hydroxylase inhibitor

Blocks hypoxia-inducible factor prolyl hydroxylase (HIF-PH) → HIF is no longer degraded
Stabilized HIF drives erythropoietin production → treats renal anemia orally
Pharmacologic altitude — thrombosis and tumor-growth theoretical concerns follow the same biology

Drugs with this mechanism (2)

Roxadustat — Oral HIF-prolyl-hydroxylase inhibitor for CKD anemia in some countries; stimulates erythropoiesis, with thrombotic concerns.
Vadadustat — Oral HIF prolyl-hydroxylase inhibitor for anemia of CKD in adults receiving dialysis.

All mechanisms · Open the interactive console ↗